Free tool
FAERS Monitor: Combivent Respimat
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021747 or its brand name (Combivent Respimat, Albuterol Sulfate, Ipratropium Bromide). Reports on generic versions are filed under their own applications.
Reports
2,765
Serious
1,506
54% of reports
Hospitalization
809
Death reported
214
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea449
- off label use232
- pneumonia195
- drug ineffective171
- fatigue170
- cough168
- headache151
- death133
- nausea132
- pain121
- asthma119
- diarrhoea112
- chronic obstructive pulmonary disease104
- product dose omission issue104
- malaise103
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 4 |
| 2012 | 6 |
| 2013 | 40 |
| 2014 | 89 |
| 2015 | 151 |
| 2016 | 216 |
| 2017 | 176 |
| 2018 | 225 |
| 2019 | 183 |
| 2020 | 236 |
| 2021 | 178 |
| 2022 | 283 |
| 2023 | 220 |
| 2024 | 276 |
| 2025 | 267 |
| 2026 | 215 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,394 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic obstructive pulmonary diseaseSignal | 104 | 15.2 | 12.6 | 1,365 |
| asthmaSignal | 119 | 8.0 | 6.7 | 727 |
| dyspnoeaSignal | 449 | 6.0 | 5.5 | 1,933 |
| pneumoniaSignal | 195 | 4.6 | 4.0 | 551 |
| coughSignal | 168 | 4.6 | 3.9 | 469 |
| product dose omission issueSignal | 104 | 2.7 | 2.2 | 110 |
| off label useSignal | 232 | 2.0 | 1.8 | 123 |
| headache | 151 | 1.8 | 1.6 | 58 |
| malaise | 103 | 1.8 | 1.5 | 36 |
| fatigue | 170 | 1.7 | 1.4 | 46 |
| pain | 121 | 1.5 | 1.3 | 20 |
| diarrhoea | 112 | 1.3 | 1.1 | 9 |
| nausea | 132 | 1.3 | 1.1 | 8 |
| death | 133 | 1.2 | 1.0 | 3 |
| drug ineffective | 171 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.